secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2026-05-14T20:05:34+00:00
Accession:  0001213900-26-056599
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Fast Track designation to INmune Bio's XPro for early Alzheimer's disease
--------------------------------------------------------------------------------

- Fast Track covers XPro for early Alzheimer's disease (MCI due to AD and mild AD dementia).
- XPro is a selective soluble TNF inhibitor targeting neuroinflammation; no approved therapy targets this pathway.
- Designation provides more frequent FDA interactions and eligibility for Rolling Review.
- Phase 2b/3 registrational trial planned as seamless adaptive design using EMACC and pTau217.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026056599/0001213900-26-056599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026056599/ea0290846-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-056599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer